MDX-018

Generic Name: MDX-018

Drug Type: Small Molecule

Background: MDX-018, also known as HuMax-Inflam, is a fully human antibody that is directed to IL-8 (interleukin-8) and may have potential application in oncology and inflammation. Trials will initially focus on studies to treat glioblastoma, a cancer of the central nervous system. Other possible indications include chronic obstructive pulmonary disease (COPD) and pustular dermatoses. In pre-clinical studies, HuMax-Inflam has been shown to inhibit tumor growth in tumor models using primary human tumors in immunodeficient mice. HuMax-Inflam was also effective in reducing disease activity in palmoplantar pustulosis patients in a clinical study.

Indication: Investigated for use/treatment in autoimmune diseases and inflammatory disorders (unspecified).

Clinical Trials

BMS-986253 in Myelodysplastic Syndromes

Phase 1

Terminated

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine
Drug: BMS-986253
Procedure: Bone Marrow Biopsy
Drug: Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine
Procedure: ECG
Procedure: Bone Marrow Aspiration

First Posted Date: 2021-12-08

Last Posted Date: 2025-04-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2

Registration Number: NCT05148234

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca

Phase 2

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Nivolumab
Drug: HuMax-IL8

First Posted Date: 2021-04-19

Last Posted Date: 2025-04-16

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 24

Registration Number: NCT04848116

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Phase 1

Recruiting

Conditions: Immune Checkpoint Inhibitors
Melanoma
Molecular Mechanisms of Pharmacological Action
Neoplasms
Neoplasms by Histologic Type
Antineoplastic Agents
Unresectable Solid Tumors
Neoplasms by Site
Antineoplastic Agents, Immunological
Nivolumab

Interventions: Drug: nivolumab
Drug: BMS-986253
Radiation: Stereotactic Body Radiotherapy (SBRT)

First Posted Date: 2020-10-01

Last Posted Date: 2024-08-16

Lead Sponsor: Jason J. Luke, MD

Target Recruit Count: 50

Registration Number: NCT04572451

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19

Phase 2

Terminated

Conditions: Solid Tumor
Sars-CoV2
Hematological Malignancy

Interventions: Drug: BMS-986253

First Posted Date: 2020-04-15

Last Posted Date: 2025-05-22

Lead Sponsor: Columbia University

Target Recruit Count: 43

Registration Number: NCT04347226

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)

Phase 2

Active, not recruiting

Conditions: Non-small Cell Lung Cancer
Hepatocellular Carcinoma

Interventions: Drug: Nivolumab
Drug: BMS-986253
Drug: BMS-813160

First Posted Date: 2019-10-10

Last Posted Date: 2025-01-17

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 48

Registration Number: NCT04123379

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)

Phase 1

Active, not recruiting

Conditions: Prostate Cancer
Adenocarcinoma of the Prostate

Interventions: Drug: Nivolumab
Drug: Degarelix
Drug: BMS-986253

First Posted Date: 2018-09-28

Last Posted Date: 2025-04-29

Lead Sponsor: Mark Stein

Target Recruit Count: 59

Registration Number: NCT03689699

Locations: 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸
Sidney Kimmel Cancer Center- Thomas Jefferson University, Philadelphia, Pennsylvania, United States
🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

and more 1 locations

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Phase 1

Active, not recruiting

Conditions: Cancer
Melanoma

Interventions: Drug: BMS-986253
Biological: Nivolumab
Biological: Ipilimumab
Other: Placebo

First Posted Date: 2018-01-17

Last Posted Date: 2024-07-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 281

Registration Number: NCT03400332

Locations: 🇺🇸
Local Institution - 0007, Lakewood, Colorado, United States
🇺🇸
Local Institution - 0087, Atlanta, Georgia, United States
🇺🇸
Local Institution - 0025, New York, New York, United States

and more 69 locations

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer

Phase 2

Recruiting

Conditions: Colon Carcinoma

Interventions: Drug: Nivolumab
Drug: BMS-986016
Drug: Ipilimumab
Drug: BMS-986253
Drug: Celecoxib 200mg

First Posted Date: 2017-01-20

Last Posted Date: 2024-04-18

Lead Sponsor: The Netherlands Cancer Institute

Target Recruit Count: 268

Registration Number: NCT03026140

Locations: 🇳🇱
Marieke van de Belt, Amsterdam, Netherlands
🇳🇱
Catharina Ziekenhuis, Eindhoven, Netherlands
🇳🇱
Spaarne Ziekenhuis, Haarlem, Netherlands

and more 3 locations